Human adult mesenchymal stem cells (MSCs) support the engineering of functional tissue constructs by secreting angiogenic and cytoprotective factors, which act in a paracrine fashion to influence cell survival and vascularization. MSCs have been isolated from many different tissue sources, but little is known about how paracrine factor secretion varies between different MSC populations. We evaluated paracrine factor expression patterns in MSCs isolated from adipose tissue (ASCs), bone marrow (BMSCs), and dermal tissues [dermal sheath cells (DSCs) and dermal papilla cells (DPCs)]. Specifically, mRNA expression analysis identified insulin-like growth factor-1 (IGF-1) , vascular endothelial growth factor-D (VEGF-D) , and interleukin-8 (IL-8) to be expressed at higher levels in ASCs compared with other MSC populations whereas VEGF-A, angiogenin, basic fibroblast growth factor (bFGF), and nerve growth factor (NGF) were expressed at comparable levels among the MSC populations examined. Analysis of conditioned media (CM) protein confirmed the comparable level of angiogenin and VEGF-A secretion in all MSC populations and showed that DSCs and DPCs produced significantly higher concentrations of leptin. Functional assays examining in vitro angiogenic paracrine activity showed that incubation of endothelial cells in ASC CM resulted in increased tubulogenic efficiency compared with that observed in DPC CM . Using neutralizing antibodies we concluded that VEGF-A and VEGF-D were 2 of the major growth factors secreted by ASCs that supported endothelial tubulogenesis. The variation in paracrine factors of different MSC populations contributes to different levels of angiogenic activity and ASCs maybe preferred over other MSC populations for augmenting therapeutic approaches dependent upon angiogenesis.
1 January 2017 in Journal of Investigative Dermatology
A major obstacle to 3‐dimensional tissue engineering is incorporation of a functional vascular supply to support the expanding new tissue. This is overcome in an in vivo intrinsic vascularization model where an arteriovenous loop (AVL) is placed in a noncollapsible space protected by a polycarbonate chamber. Vascular development and hypoxia were examined from 3 days to 112 days by vascular casting, morphometric, and morphological techniques to understand the model's vascular growth and remodeling parameters for tissue engineering purposes. At 3 days a fibrin exudate surrounded the AVL, providing a scaffold to migrating inflammatory, endothelial, and mesenchymal cells. Capillaries formed between 3 and 7 days. Hypoxia and cell proliferation were maximal at 7 days, followed by a peak in percent vascular volume at 10 days (23.2±03.14% compared with 3.5±92.68% at 3 days, P <0.001). Maximal apoptosis was observed at 112 days. The protected space and spontaneous microcirculatory development in this model suggest it would be applicable for in vivo tissue engineering. A temporal window in a period of intense angiogenesis at 7 to 10 days is optimal for exogenous cell seeding and survival in the chamber, potentially enabling specific tissue outcomes to be achieved.—Lokmic, Z., Stillaert, F., Morrison, W. A., Thompson, E. W., Mitchell, G. M. An arteriovenous loop in a protected space generates a permanent, highly vascular, tissue‐engineered construct. FASEB J. 21, 511–522 (2007)
1 March 2008 in Tissue Engineering Part B: Reviews
The ultimate survival of tissue-engineered constructs in vivo depends on the provision of an adequate blood supply to the engineered tissue and the capacity of the engineered microcirculation to connect with the existing recipient circulation. Techniques for the vascularization of tissue-engineered constructs can be broadly grouped into in vitro and in vivo approaches that rely on the presence of a pro-angiogenic microenvironment. Significant advances have been made in resolving the problem of microcirculatory network formation for large 3-dimensional constructs; however, issues concerning construct–host vessel connection, expansion of vascular volume accompanying growing tissue, and prevention of premature or excessive vascular regression remain to be resolved. This review provides an overview of current approaches to creating microcirculatory networks with respect to the cells involved, growth factors, growth factor delivery systems, and scaffold properties required to engineer a permanent microcirculatory network for tissue-engineered constructs. In addition, the review examines concerns related to vascular remodeling and regression reported in some tissue-engineering models.